Dale Presser, MD
Cardiovascular Disease · Covington, LANPI 1922062512
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,588 of the $14,763 with a category attached, or 85.3%. 33 manufacturers reported payments, led by Medtronic at 51.7% of the total. Reporting peaked in 2023 at $3,641 and has fallen 69.1% since, to $1,126 in 2025.
Across 572 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Novartis$749
- Kestra Medical Technology Services, Inc.$597
- Amgen$566
- E.r. Squibb & Sons, L.L.C.$544
- Johnson & Johnson$538
- plus $4K from 27 others
Across 38 payments — averaging $45,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.7M
- Amgen$65K
- AstraZeneca$3K
What the payments were for
- Travel & lodging$2,16415%
- Food & beverage$12,58885%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 177 | $7,626 |
| Novartis | 50 | $749 |
| Kestra Medical Technology Services, Inc. | 11 | $597 |
| Amgen | 43 | $566 |
| E.r. Squibb & Sons, L.L.C. | 29 | $544 |
| Johnson & Johnson | 34 | $538 |
| Merck | 29 | $478 |
| Pfizer | 26 | $395 |
| Boehringer Ingelheim | 19 | $364 |
| Abbott | 18 | $316 |
| AstraZeneca | 20 | $305 |
| Abiomed | 32 | $286 |
| Boston Scientific | 7 | $265 |
| Sanofi-aventis U.S. LLC | 16 | $254 |
| Kowa Pharmaceuticals America, Inc. | 16 | $239 |
| Esperion Therapeutics, Inc. | 17 | $226 |
| Impulse Dynamics (USA) Inc. | 3 | $153 |
| Inspire Medical Systems, Inc. | 1 | $122 |
| Shockwave Medical, Inc | 1 | $120 |
| Atricure, Inc. | 1 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $114 |
| Astellas Pharma US Inc | 3 | $58 |
| Itamar Medical Inc | 1 | $56 |
| Davol Inc. | 1 | $53 |
| Scpharmaceuticals Inc. | 2 | $39 |
| Edwards Lifesciences | 1 | $36 |
| Novo Nordisk | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $32 |
| Stryker | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Teleflex LLC | 1 | $19 |
| Bayer | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evera$501
- AZURE XT DR MRI SURESCAN$477
- Assure WCD$436
- Micra$379
- SYMPLICITY G3$177
- HawkOne$171
- LINQ II$143
- MyCareLink$131
- JARDIANCE$125
- Inspire Upper Airway Stimulation System$122
- Vascular Lithotripsy$120
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$116
- OPTIMIZER SMART SYSTEM$115
- Advisa$109
- Azure$107
- Reveal LINQ$104
How this compares
$14,763 in reported general payments places this provider in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 985 | $853,706 |
| EntrestoSacubitril/Valsartan | 310 | $287,158 |
| Repatha SureclickEvolocumab | 263 | $204,054 |
| XareltoRivaroxaban | 147 | $134,474 |
| BrilintaTicagrelor | 90 | $55,229 |
| MultaqDronedarone Hcl | 20 | $30,240 |
| JardianceEmpagliflozin | 15 | $15,072 |
| NexletolBempedoic Acid | 36 | $14,382 |
| SotalolSotalol Hcl | 618 | $12,995 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 41 | $12,623 |
| NexlizetBempedoic Acid/Ezetimibe | 27 | $11,690 |
| FarxigaDapagliflozin Propanediol | 19 | $11,670 |
| Praluent PenAlirocumab | 15 | $9,214 |
| Ranolazine ErRanolazine | 130 | $9,165 |
| Metoprolol Succinate | 890 | $8,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $395 | $853,706985 claims |
| NovartisEntresto | $749 | $287,158310 claims |
| Johnson & JohnsonXarelto | $538 | $134,474147 claims |
| AstraZenecaBrilinta, Farxiga | $305 | $66,899109 claims |
| Sanofi-aventis U.S. LLCMultaq | $254 | $30,24020 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $226 | $26,07263 claims |
| Boehringer IngelheimJardiance | $364 | $15,07215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Covington
- Russell ReedCovington$13K
- Georges El Khoury AntounCovington$11K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
- Darrell SoletMorgan City$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.